Author

Kyle M. LaPak

Washington University in St. LouisORCID 0000-0002-7571-4222Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Assay:metabolomics· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Michael B. MajoriD· 2 shared Anayat BhatiD· 1 shared Brittany M. BowmaniD· 1 shared Celeste M M. KarchiD· 1 shared Chorlada PaiboonrungruangiD· 1 shared Daved H. FremontiD· 1 shared Dennis GoldfarbiD· 1 shared Emily WilkersoniD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Michael B. MajorORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TMEM106B mediates ACE2-independent replication of the SARS-CoV-2 S-E484D variant in airway-derived cell models

Ming Xia, Qibo Wang, Maritza Puray-Chávez, Kyle M. LaPak, Zhuoming Liu, Sathvik Palakurty, Paul W. Rothlauf, Sean Hui, Natalie Stegman, Marjorie Cornejo Pontelli, Jacob Marsh, Anayat Bhat, Celeste M M. Karch, Daved H. Fremont, Ramón Lorenzo-Redondo, , Sebla B. Kutluay

This study identifies TMEM106B as an alternative receptor for SARS-CoV-2 S-E484D variant entry, independent of ACE2, in airway-derived cell models.

bioRxiv · Oct 30, 2026 · PreprintMicrobiology

Pyrimethamine and a potent analogue WCDD115 inhibit NRF2 by suppressing DHFR and one-carbon metabolism

Julius Chembo, Brittany M. Bowman, Kyle M. LaPak, Emily Wilkerson, Chorlada Paiboonrungruang, Kevin Cho, Matthew R. Medcalf, Gary J. Patti, Roland E. Dolle, Xiaoxin Luke Chen, Paul Zolkind, Michael B. Major

This paper identifies Pyrimethamine and its derivative WCDD115 as potent inhibitors of NRF2 by targeting DHFR and one-carbon metabolism, with WCDD115 showing 22-fold greater efficacy.

bioRxiv · Feb 13, 2025 · PreprintCancer Biology